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Yun-Ju Lai, Ph.D.(c), M.S., R.N. 
Relationships among Optimism, Inflammation, and Stroke Recovery 
May, 2019 
Objective: Post-stroke inflammation is detrimental to the brain and results in an 
unfavorable recovery. Optimism has been associated with lower inflammation and better 
health outcomes among people with medical conditions, but no studies have assessed this 
association in the stroke population. The overall goals were to examine the relationships 
among optimism, stroke severity, physical disability, and inflammation during 
hospitalization and evaluate the relationships among optimism, inflammation, and stroke 
recovery over the three-month post-stroke period.  
Methods: This study was a secondary analysis of data prospectively collected from the 
BioRepository of Neurological Diseases biobank. Outcomes included optimism, stroke 
severity, physical recovery, and inflammatory markers (IL-6, TNF-α, and CRP). 
Spearman’s correlation, Wilcoxon signed-rank test, multiple linear regression, and 
mixed-effect regression model were used to determine the relationships among the 
variables.  
Results: A total of 49 subjects at baseline, with 13 at 3-month follow-up were recruited. 
The results indicated that subjects with higher optimism showed less stroke impairment 
and lower level of CRP at baseline compared to those with lower optimism. Additionally, 
optimism was associated with less stroke severity and lower IL-6 and CRP levels over the 
first three months after stroke.  
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Conclusion: Optimistic stroke survivors showed lower inflammation and better stroke 
recovery. By understanding this relationship may provide a scientific framework whereby 
new strategies for stroke recovery can be developed in the future. 
Keywords: optimism, inflammation, stroke recovery
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Summary of Study 
The dissertation study entitled “ Relationships among Optimism, Inflammation, 
and Stroke Recovery” is presented in this book. The purpose of the study was to 
examine the relationships among optimism, stroke severity, physical disability, and 
inflammation during hospitalization and evaluate the relationships among optimism, 
inflammation, and stroke recovery over the three-month post-stroke period. Approval 
for this study was sought from the Committee for the Protection of Human Subjects 
(CPHS) at the University of Texas Health Science Center at Houston’s Institutional 
Review Board and approval was attained in June, 2018.  
This book includes (A) a proposal of the study which described study specific 
aims, background and significance, research design and methods, and research 
participant risk and protection; (B) a manuscript entitled “Blood Biomarkers for 
Physical Recovery in Ischemic Stroke: A Systematic Review” which identified 34 
biomarkers were significantly associated with physical recovery after ischemic stroke: 
(1) immune response (15, 44%); (2) lipids/metabolism (4, 12%); (3) neuronal function 
(4, 12%); and (4) blood vessel/circulation (11, 32%). Of the predictive biomarkers 
associated with 1-month recovery, 60% (6 of 10) was classified into blood 
vessel/circulation; 54% (14 of 26) of the biomarkers associated with 3-6 month physical 
recovery involved the immune response; and (C) a manuscript entitled “ Relationships 
among Optimism, Inflammation, and Stroke Recovery”  which found stroke survivors 
with higher optimism showed less stroke impairment and lower level of CRP at baseline 
compared to those with lower optimism. Additionally, optimism was associated with 
less stroke severity and lower IL-6 and CRP levels over the first three months after 
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stroke. A total of 49 subjects at baseline, with 13 at 3-month follow-up were recruited in 
this study. 
The appendixes contain the Institutional Review Board (IRB) approvals, 
instruments,  and the demographic datasheet used for data collection. The final section 
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Background: Post-stroke inflammation is detrimental to the brain and results in 
an unfavorable recovery. Optimism has been associated with lower inflammation and 
better health outcomes among people with cardiac or Parkinson’s diseases, but there are 
currently no such studies that have been reported in post-stroke population. Objectives: 
The overall objectives of this study are to (1) examine the relationships between 
optimism, stroke severity, physical disability, and inflammation during the time of 
hospitalization, and (2) examine the longitudinal relationships between optimism, 
inflammation, and stroke recovery over the three-month post-stroke period. The long-
term goal is to develop a suitable psychological intervention strategy to boost stroke 
survivors’ optimism levels which may accelerate stroke recovery and reduce risk of 
recurrent strokes in the future. Methods: This study will be a secondary analysis of data 
previously collected from the BioRepository of Neurological Diseases biobank, utilizing 
an observational quantitative design. Levels of optimism, stroke severity, physical 
disability, and plasma inflammatory cytokines, including IL-6, TNFα, and CRP will be 
measured during the time of hospitalization (T1) and three months following stroke onset 
(T2). Under the first aim, the correlations among optimism level and stroke severity, 
physical disability, and levels of inflammatory markers at T1 will be analyzed by Pearson 
or Spearman correlation coefficient. For the second aim, the correlations of optimism 
with outcomes of stroke recovery and inflammation will be tested by longitudinal 
analysis. Expected outcomes: The central hypothesis is that patients with higher levels 
of optimism will show less stroke severity, less physical disability, decreased 




compared to those with lower levels of optimism. Significance and innovation: The 
proposed research is significant because it is expected to provide the better understanding 
of mechanisms underlying the role of optimism in post-stroke inflammation and physical 
recovery. The research proposed in this application is innovative, in the applicant’s 
opinion, because it first (i) examines stability of optimism levels in stroke population by 
longitudinal analysis; (ii) explains association of optimism with acute and chronic 
inflammation following stroke; and (iii) explains relationships between optimism, stroke 
severity, physical disability, and stroke recovery. The rationale for this project is that 
understanding the relationship between optimism and stroke recovery and the associated 
mechanism is likely to provide a scientific framework whereby new strategies for stroke 









To date, stroke is the fifth cause of death and the most common cause of long-
term disability in the United States (Benjamin et al., 2018). Motor impairment, sensory 
dysfunction, and dysphasia are common symptoms of stroke. Up to 30% of stroke 
survivors suffer permanent disability, and 20% of survivors required inpatient 
rehabilitation within three months after a stroke event (Apostolopoulou, Michalakis, 
Miras, Hatzitolios, & Savopoulos, 2012). In addition, restriction of blood supply to the 
brain results in decreased delivery of oxygen and nutrients, potentially leading to a 
permanent brain injury. Inflammatory response induced by damaged and dead cells 
following stroke may be more detrimental to the brain (Iadecola & Anrather, 2011; 
Wang, Tang, & Yenari, 2007) and result in an unfavorable recovery (Dziedzic, 2015; J. 
Y. Kim, Kawabori, & Yenari, 2014). 
Optimism is defined as a mood or attitude related to positive expectations of the 
future and is considered to be a personality trait (Scheier, Carver, & Bridges, 1994; Tiger, 
1979). It has been associated with health promotion and disease prevention, such as 
improvement of surgical recovery (Tindle et al., 2012), post-stroke recovery (Shifren & 
Anzaldi, 2018a), and decreased the risk of stroke (E. S. Kim, Park, & Peterson, 2011). 
The previous study also found that optimism level may be significantly increased by 
various psychological interventions and thereby enhance well-being (Antoni et al., 2001). 
Accumulating evidence indicates that optimistic people have better mental and physical 
health (Gison, Rizza, Bonassi, Donati, & Giaquinto, 2015). However, the mechanisms 
implicated in the links between optimism, inflammation, and post-stroke recovery remain 




optimism, inflammation, and physical recovery in the post-stroke population. Without 
such information, the understanding of the connection between mind and body will likely 
remain limited.  
The long-term goal is to develop a suitable intervention strategy to boost stroke 
survivors’ optimism levels which will accelerate stroke recovery and reduce the risk of 
recurrent strokes in the future. The overall objectives of this study are to (i) examine the 
relationships between optimism, stroke severity, and inflammation at stroke onset, and 
(ii) examine the longitudinal relationships between optimism, inflammation, and physical 
recovery over three months from stroke onset. The central hypothesis is that patients with 
higher levels of optimism will show less stroke severity, less physical disability, 
decreased inflammation, and better physical recovery during the first three months after 
stroke compared to those with lower levels of optimism. The success of this study may 
delineate the relationships between optimism and post-stroke recovery, as well as identify 
the potential inflammatory markers which may predict the prognosis for recovery from 
stroke. The rationale for this project is that understanding the relationship between 
optimism and stroke recovery and the associated mechanism is likely to provide a 




To attain the overall objectives, we 
propose a pilot longitudinal study in stroke 
patients. Assessments of optimism, stroke 
severity, physical disability, and plasma 
inflammatory cytokines (IL-6, TNFα, and 
CRP) will be done during the time of 
hospitalization (T1) and three months post-
stroke (T2). The following two specific aims 
will be pursued (Figure 1):  
Aim 1: Examine the relationships between optimism, stroke severity, physical 
disability, and inflammation during the time of hospitalization.  
Working hypothesis: stroke patients with higher levels of optimism during the time of 
hospitalization will show less stroke severity, less physical disability, and lower levels of 
pro-inflammatory cytokines compared to those with lower optimism levels. 
Aim 2: Examine the longitudinal relationships between optimism, inflammation, 
and stroke recovery at three-month post-stroke period.  
Working hypothesis: patients’ levels of optimism will remain stable over the three 
months, and more optimistic patients will develop less inflammation and accelerated 
stroke recovery over the 3-month post-stroke period.  
The expected findings of this study provide the critical information on 
relationships between optimism, inflammation, and stroke recovery. Particular concern 
was given to boost levels of optimism on physical health among stroke population. The 
knowledge gained from this research may provide a positive impact on clinical practice 
 






and be used to design and test an intervention to augment stroke survivors’ optimism 
level which can improve post-stroke recovery. 
Background and Significance 
According to the recent study by Benjamin et al. (2018), approximately 795,000 
Americans have strokes every year. Stroke is the most common neurological disease in 
the adult population worldwide, and the third cause of chronic disability (Feigin, 
Norrving, & Mensah, 2017). Motor impairment, sensory dysfunction, and aphasia are 
common symptoms of stroke. About 25 - 74% of stroke survivors are dependent in 
activities of daily living (ADL) (Miller et al., 2010). Post-stroke rehabilitation is a 
continuum, starting within days of stroke onset and ending only when it no longer 
produces any positive effect. Prior studies indicated that 48 - 91% of physical recovery 
occurred within the first three months after stroke (Lee et al., 2015; Stinear, 2017; Wade, 
Wood, & Hewer, 1985). To date, improvements in acute stroke care have reduced stroke-
related mortality over the past two decades. However, because of the increased survival 
rate, many of the survivors are left with severe disability, placing a tremendous burden on 
the healthcare system and caregivers (F. Mu et al., 2017). Therefore, accelerating 
physical recovery and preventing of recurrent stroke have become new challenges that 
await exploration. 
Damaged cells caused by stroke may evoke a massive upregulation of the 
inflammatory response (Dirnagl, Iadecola, & Moskowitz, 1999). Pro-inflammatory 
cytokines, such as IL-6, TNFα or CRP, attract innate immune cells from circulatory 
system to infiltrate the damaged tissue and support post-stroke healing (Lakhan, 




infiltrated immune cells may produce cytotoxic mediators that prolong the inflammatory 
response, increase brain damage and contribute to edema formation and hemorrhagic 
transformation (Hu et al., 2016). These secondary complications commonly influence 
stroke outcomes and leave an individual with residual impairment of physical, 
psychological, and cognitive functions. Hence, properly regulating the post-stroke 
inflammation may be a therapeutic strategy to reduce the secondary brain injury and 
enhance post-stroke recovery (Simats et al., 2016). 
Optimism is conceptually defined as positive expectations of the future (Scheier 
& Carver, 1985). It is considered a personality trait, but also a positive psychological 
factor (Conversano et al., 2010b; Scheier & Carver, 1985). Studies have shown that 
optimistic expectation may change over time whenever a person’s situation changes, such 
as in high-stress situations (Atienza, Stephens, & Townsend, 2004; Segerstrom, 2007). A 
meta-analysis indicated that psychological intervention approaches, such as Best Possible 
Self or cognitive-behavior therapy may be able to significantly augment level of 
optimism among different populations (Malouff & Schutte, 2017). 
Optimistic individuals tend to be positive about events happened in their daily 
life. Accumulated studies have found that optimism is associated with beneficial health 
outcomes. For example, optimistic people report more resilience to stress, faster recovery 
after cardiac bypass surgery (Ronaldson et al., 2014; Tindle et al., 2012), less chronic 
inflammation in older adults (Ikeda et al., 2011) and lower blood pro-inflammatory 
cytokines in patients with cardiovascular diseases (Roy et al., 2010). Therefore, optimism 
is not only critical to maintaining healthy state mentally, but it may also improve the 




disability. A qualitative study found that optimistic stroke survivors may exhibit more 
confidence to face the challenges of stroke recovery (Jones, Mandy, & Partridge, 2008). 
Moreover, a recent study also showed that stroke survivors with higher levels of 
optimism develop fewer depressive symptoms and better perceived physical health 
during rehabilitation (Shifren & Anzaldi, 2018a). However, no studies have examined the 
links between optimism, inflammation, and physical recovery among stroke population.  
The purpose of this study is to examine the relationships between optimism, 
inflammation, and physical recovery among stroke population. Given the evidence of 
associations of optimism, inflammation, and physical health with multiple diseases, but 
not stroke, it is important to determine how optimism is associated with inflammation and 
post-stroke recovery. With the understanding of mechanisms underlying the role of 
optimism in post-stroke inflammation and physical recovery, psychological interventions 
for boosting optimism may be developed. 
Conceptual Framework 
To examine the relationships between optimism, inflammation, and post-stroke 
recovery, the conceptual framework will adapt from Kang’s biobehavioral model (Kang, 
Rice, Park, Turner-Henson, & Downs, 2010). It includes (1) psychosocial factors, such as 
stress or optimism, represents psychological and social factors that influence health; (2) 
biological factors, such as immune or endocrine functions, are defined as body’s 
physiological reactions; and (3) health outcomes are a change in the health status of an 
individual, group or population.The model can explore the relationship between 
psychosocial factor (optimism), biological factor (inflammation), and health outcomes 




contributes to the 
understanding of health and 
health-related outcomes and 
may serve as a basis for 
developing and evaluating 
appropriate interventions such 
as cognitive behavioral 
therapies to promote, restore, 
and maintain health. Through 
this model, we can have a 
better understanding of the interaction between mind and body among post-stroke 
population. The successful completion of the proposed study will provide the critical 
evidence to link optimism, inflammation, and physical recovery in the stroke population.  
Innovation 
Optimism has been associated with decreased inflammatory response among 
people with cardiovascular diseases (Roy et al., 2010) and better functional outcomes and 
quality of life in patients with Parkinson’s disease (Gison et al., 2015) or traumatic brain 
injuries (Ramanathan, Wardecker, Slocomb, & Hillary, 2011). However, there are no 
studies that have examined the links between optimism and inflammation in stroke 
recovery. As such, we believe this study is innovative because it first:  
1. Examines stability of optimism levels in stroke population by longitudinal analysis. 
2. Explains association of optimism with acute and chronic inflammation following 
stroke. 
 
Figure 2. The conceptual model. Conceptual 
framework of psychosocial factor, physiological 
factor, and health outcomes post-stroke population is 





3. Explains relationships between optimism, stroke severity, physical disability, and 
stroke recovery.   
In this regard, understand the association of optimism in inflammation and post-stroke 
recovery may serve as a basis for developing and evaluating appropriate psychological 
interventions to boost optimism to accelerate stroke recovery in the future. 
Research Design and Methods 
 To understand how optimism influences stroke severity, inflammation, and 
recovery, we will test the working hypotheses of Aim 1 and Aim 2. Minimal evidence 
regarding the relationships between these variables at stroke onset and 3-month following 
stroke. Filling this gap is likely to improve the understanding of the role of optimism in 
physical function, stroke recovery and inflammation over a three-month period. Upon 
completion of this study, less stroke severity, decreased physical disability, lower 
inflammation, and better recovery will be expected in more optimistic stroke survivors. 
Research Design 
This study will be a secondary analysis of data previously collected from the 
BioRepository of Neurological Diseases 
biobank, utilizing an observational 
quantitative design. This study will 
investigate how optimism influences (1) 
stroke severity, physical disability, and 
inflammation during the time of 
hospitalization (T1) in Aim 1; (2) stroke 
Figure 3. Timepoints of sample 
collection. LOT-R indicates Revised 
Life Orientation Test; NIHSS indicates 
National Institutes of Health Stroke 





recovery and inflammation over a three-month post-stroke period (T1 and T2) in Aim2 
(Figure 3).  
Sample and Setting 
Inclusion criteria in this study are: the participant is (1) aged ≥ 18 years; (2) 
diagnosed with an ischemic stroke. 
Exclusion criteria are: the participant is (1) diagnosed with transient ischemic 
attack or intracerebral hemorrhage, including secondary hemorrhage on control computed 
tomography or magnetic resonance imaging (to avoid confounding effects of hematoma-
induced inflammation (2) with underlying vascular lesions or traumatic brain injury, 
systemic malignancy, autoimmune disease, or immunosuppression (defined as current 
(>28 day) use of any immunosuppressive drugs; and (3) unable to provide informed 
consent will be excluded.  
For Aim 1, we assume that the minimum correlation coefficient between 
optimism and stroke severity, physical disability, and inflammation is 0.4 (Ikeda et al., 
2011; Roy et al., 2010). To identify a correlation coefficient with 80% of power at a type 
I error of 0.05, we need 46 participants (Bujang & Baharum, 2016). For Aim 2, we need 
to compare the outcomes of stroke recovery and inflammation between optimism and 
non-optimism groups. Based on related articles and our preliminary data, we assume that 
the mean differences are 8.2 with a standard deviation (SD) of 8.1 for NIHSS, 2.3 with a 
SD of 1.7 for mRS, and 1.8 with a SD of 2.2 for CRP. The required sample sizes for the 
three variables are 24, 14, and 36, respectively, to achieve 80% of power at a type I error 
of 0.05 using longitudinal data analysis (Hedeker, Gibbons, & Waternaux, 1999).The 




for multiple testing. As a result, the sample size 46 from Aim 1 is sufficient for Aim 2 as 
well. Additionally, with an estimated dropout rate of 15%, 54 participants need to be 
recruited in this study. 
Data Collection 
The data will be obtained  from the BioRepository of Neurological Diseases 
biobank . The data, , including optimism, stroke severity, and physical disability will 
have previously been  gathered at two time points, (1) T1: during the time of 
hospitalization and (2) T2: three months, with windows of ± 14 days, after stroke onset. 
Participant’s demographic and clinical data, such as age, gender, race/ethnicity, and 
medical histories will be extracted from the biobank (Figure 3). Peripheral venous blood 
samples will have been  obtained from participants within 24±6 hr from admission (T1) 
and three months ±14 days after stroke onset (T2). 
Measurements 
The main predictor variable is level of optimism which will be measured by LOT-
R (Scheier et al., 1994). The range of scores is from zero to 24, with higher scores 
indicating higher levels of optimism. It includes 10 items; four of them are filler items 
which are not used in scoring. Of the six items that are scored, three are keyed in a 
positive direction and three in a negative direction. The respondents indicate the extent to 
which they agree with each item on a 5-point Likert scale that ranges from strongly 
disagree to strongly agree. The acceptable internal consistency of LOT-R was reported as 
Cronbach’s α of 0.82 (Shifren & Anzaldi, 2018a) in stroke population and stability (test-
retest reliability) over a 4-month period (r = 0.79) in college students (Scheier et al., 




indicates low optimism, 14-18 moderate optimism and 19-24 high optimism (Kreis et al., 
2015).  
The outcome variables are (1) Severity of stroke will be evaluated by the National 
Institutes of Health Stroke Scale (NIHSS) by the certified neurologist at T1 and T2 (Brott 
et al., 1989). The data will be extracted from the biobank  at T1 and T2. The range of 
scores is from zero to 42, with lower scores indicating less impairment. The acceptable 
interrater reliability was reported as an intraclass correlation coefficient of 0.82 
(Goldstein & Samsa, 1997) and high content validity in stroke population (Kasner, 
2006a). (2) Physical disability after a stroke will be assessed with modified Rankin Scale 
(mRS) by the certified neurologist at T1 and T2 (Banks & Marotta, 2007). The data will 
be extracted from the biobank  at T1 and T2. The range of mRS scores is from zero to 
six, with lower scores indicating less disability. The acceptable internal consistency of 
mRS was reported as Cronbach’s α of 0.89 in stroke survivors (Wei, Han, Wei, & Duan, 
2015). (3) IL-6, TNF-α, and CRP are defined as plasma inflammatory biomarkers. Levels 
of biomarkers will be measured at T1 and T2 by multiplex ELISA. The assays have a 
lower limit of sensitivity (minimum detectable concentration) of 1-2 pg/ml, and the 
average intra- and inter-assay coefficients of variations reported by the manufacturer are 
<10% and <10%, respectively.  
Blood sample will be collected as follows: Immediately after blood samples are 
collected, participants will be de-identified and assigned a unique subject number. Blood 
samples will be labeled with preprinted barcode labels. Plasma will be separated by 
centrifuging at 1,000-2,000xg for 10 minutes. Following centrifugation, plasma will be 




handling. To avoid freeze-thaw cycle, plasma will be separated into aliquots at a volume 
of 0.1ml. Plasma samples will be analyzed for inflammatory markers, including IL-6, 
TNF-α, and CRP by multiplex enzyme-linked immunosorbent assay (ELISA) (BioRad, 
Hercules, CA) in the end of each month. All samples will be analyzed by a researcher 
blinded to participant’s stroke severity (NIHSS) and physical disability (mRS). Rest of 
plasma will be stored in -80°C freezer for future study. Freezers for storage will be 
located on the 3rd floor of the UTHealth McGovern Medical School MSE R319 (Dr. 
McCullough’s laboratory). 
Potential confounder variables including age, gender, history of stroke, stroke 
severity, and medical histories, medicine records, and social support will also be 
examined in both Aim 1 and Aim 2. 
Statistical Procedures 
Following a test of statistical normality, descriptive statistics, including the 
number of participants, age, gender, and race/ethnicity will be expressed as mean ± SD or 
median with interquartile range. To demonstrate the hypothesis of Aim 1, we will 
calculate the Pearson or Spearman correlation coefficient among optimism score and 
stroke severity, physical disability, and levels of inflammation biomarkers at T1 using 
SPSS 25.0 for Windows (SPSS Inc., Chicago, IL). The correlation among variables and 
potential confounders will be analyzed by multiple linear regression. Values of p < 0.05 
will be considered statistically significant. 
To validate the hypothesis of Aim 2, we will compare the outcomes of stroke 
recovery and inflammation between optimism and non-optimism groups by longitudinal 




model. In addition, we will use continuous optimism score in the longitudinal analysis for 
further details. Bonferroni correction will be used to adjust for the multiple testing. For 
missing data, if missing is random, we will analyze the data as it is. Otherwise, we will 
follow Ibrahim and Molenberghs’ method for data analysis (Ibrahim & Molenberghs, 
2009). Values of p < 0.05 will be considered statistically significant. 
Data Management 
All study data will be entered into a secure online database created and managed 
by UT Houston Data Management and Analysis Core (DMAC) at the Department of 
Neurology / Stroke Institute. The database will be created using the Research Electronic 
Data Capture (REDCap) database management system. Data will be stored on secure 
zone 100 UTHealth servers which are managed by UTHealth School of Bioinformatics 
and have been approved for collection and storage of patient information. Access to the 
database will follow all security protocols of UTHealth Houston. Access will be managed 
centrally via the DMAC and will be assigned based on personnel roles on the principle of 
least privilege (i.e. access only to the information and resources that are necessary for 
individuals’ legitimate purpose and function). All personnel obtaining access to the 
database will undergo individual identification verification and management system of 
the UTHealth Houston. Other than assigned DMAC personnel, no users will have the 
capacity to download raw data. Within the DMAC no downloaded data with PHI will be 
stored on local computers or removable media. Such data will be stored and managed on 
UTHealth Neurology Servers (NAS). Data for analyses will be generated by DMAC 





Strengths of the Proposed Study 
The proposed study is unique in being the first study of the relationships between 
optimism, inflammation, stroke severity, and functional recovery in post-stroke 
population. Detection of inflammatory biomarkers in blood at the time of admission and 
3-month after stroke onset can provide valuable information regarding the 
pathophysiology of disease and predict patient recovery better than standard clinical 
prediction tools (Misra et al., 2017; Unden et al., 2009). Furthermore, the success of this 
study may help design a proper psychological intervention to boost the level of optimism.  
Research Subject Risk and Protection 
Participants may involve potential risks of a breach of confidentiality. The risks 
will be minimized by (1) Removing direct participant identifiers (i.e., names, medical 
record numbers) from samples and associated data stored in the research repository. All 
participants will be assigned a unique subject number (de-identified). All samples will be 
labeled with preprinted barcode labels using the same numbering system. (2) Limiting 
access to samples and associated data contained within the research repository to the 
research team; (3) Securing in a separate location, and limiting access to information 
linking codes (i.e., linkage codes) assigned to the repository samples and associated data 
with direct participant identifiers. 
Potential Pitfalls & Alternative Strategies 
The main potential pitfall is loss of confidentiality of the data. This risk will be 
minimized as above under Potential Risks and Controls. Moreover, because the cytokine 
analysis may involve more complicated analysis, we will be assisted by Dr. Liang Zhu in 




will routinely consult with Dr. Rebecca Casarez at the UTHealth Cizik School of Nursing 
and Dr. Louise McCullough at the Department of Neurology, UTHealth McGovern 
Medical School. They will supervise the project and provide professional opinions. 
Ethical Aspects of the Proposed Research 
Participant’s medical condition will be managed according to the guidelines 
published by the American Stroke Association (Powers et al., 2018). This study will be 
approved by the UTHealth CPHS. 
Timeline of the Proposed Research 
Year 2018 2019 
Month 6 7 8 9 10 11 12 1 2 3 
Recruitment X X X X X      
Data Collection X X X X X X X    
Data analysis: Aim 1      X X X    
Data analysis: Aim 2       X X X  
Report preparation       X X X  
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Stroke is a common cause of physical disability. Biomarkers have been used to predict 
prognosis in ischemic stroke, but studies linking biomarkers to physical recovery from 
ischemic stroke have not been systematically evaluated since 2011. The purpose of this 
paper is to report the findings of a systematic review of the intervening literature to 
identify potential predictive biomarkers for recovery of physical function following 
ischemic stroke. The PubMed, Embase, and CINAHL databases were searched for 
studies reported between January 1, 2011, and September 18, 2018. Search criteria were 
adult ischemic stroke patients, blood sample collection within 24±6 hrs of stroke onset, 
and outcome measures, including physical function. Identified from 18 studies and 
representing four biological classifications, 34 biomarkers were significantly associated 
with physical recovery after ischemic stroke: (1) immune response (15, 44%); (2) 
lipids/metabolism (4, 12%); (3) neuronal function (4, 12%); and (4) blood 
vessel/circulation (11, 32%). Of the predictive biomarkers associated with 1-month 
recovery, 60% (6 of 10) was classified into blood vessel/circulation; 54% (14 of 26) of 
the biomarkers associated with 3-6 month physical recovery involved the immune 
response. Blood biomarkers might provide useful information to improve the prediction 
of physical outcome after ischemic stroke. The data suggest that biomarkers from four 
biological classifications may predict physical recovery in patients after ischemic stroke. 
 







Stroke is the 5th leading cause of death in the U.S. (Benjamin et al., 2018), with an 
annual incidence of approximately 795,000 cases. Ischemic stroke accounts for 87% of 
all strokes (Benjamin et al., 2018). In addition, stroke is the most common neurological 
disease in the adult population worldwide, and the third leading cause of chronic 
disability (Feigin et al., 2017). Up to 74% of stroke survivors are dependent in activities 
of daily living (Miller et al., 2010). 
Motor impairment, sensory dysfunction, and dysphasia are common 
manifestations of stroke. Up to 30% of stroke survivors in the U.S. suffer permanent 
disability, and 20% of survivors require inpatient rehabilitation within 3 months after 
stroke (Creutzfeldt, Holloway, & Walker, 2012). Improvements in acute stroke care have 
reduced stroke-related mortality over the past two decades; however, the increased 
survival rate leaves many survivors with severe disability, placing a tremendous burden 
on the healthcare system and caregivers (F. Mu et al., 2017).  
Prior studies indicated that up to 91% of physical recovery occurs within the first 
3 months after stroke (Lee et al., 2015). Physical recovery includes motor function, 
sensation, language, and swallowing ability (Harvey, 2015). Because these physical 
functions often are interdependent, all are included in the assessment of recovery after 
stroke, and no single measure fully describes disability or functional outcome from 
stroke.  
The most widely used scales for stroke outcomes are the National Institutes of 
Health Stroke Scale (NIHSS), the modified Rankin Scale (mRS), and the modified 




quantify stroke severity based on language, motor function, sensory loss, consciousness, 
visual fields, extraocular movements, coordination, neglect, and speech (Adams et al., 
1999). Global disability, with a focus on mobility, is assessed with the mRS (Banks & 
Marotta, 2007). Functional outcomes and daily life activities are measured with the mBI 
(Ohura, Hase, Nakajima, & Nakayama, 2017). A statistically significant inverse 
correlation has been demonstrated between the mRS and the mBI in the post-stroke 
population (Memis, Kozanoglu, Kelle, & Goncu, 2016); the more disability on the mRS, 
the less independent the patient scores on the mBI. Furthermore, admission NIHSS score 
has been found to be positively correlated with mRS score over time (Saver & Altman, 
2012).  
A biomarker is a molecule measured in blood, urine, cerebrospinal fluid, or tissue, 
or an imaging test, such as magnetic resonance imaging or computed tomography. Blood 
biomarkers have been commonly used to provide prognostic information following 
ischemic stroke. For example, levels of brain natriuretic peptide (BNP), D-Dimer, matrix 
metallopeptidase-9 (MMP-9), and S100B in blood were positively correlated with 
mortality at 4 months post-stroke (Iemolo, Sanzaro, Duro, Giordano, & Paciaroni, 2016). 
Cardiac markers, such as BNP and troponin, have been shown to have a consistent 
association with poor outcome after ischemic stroke (Whiteley, Chong, Sengupta, & 
Sandercock, 2009). Moreover, the most recent systematic review of blood biomarkers for 
acute stroke found that levels of glucose, glutamate, and fibrinogen at stroke onset were 
associated with poor prognosis in ischemic stroke patients (Hasan, McColgan, Bentley, 




Emerging biomarkers from new discoveries in the field of stroke research may 
help predict stroke outcome and recovery. As the Hasan et al. (Hasan et al., 2012) 
publication is the most recent and relevant systematic review, the purpose of this review 
was to synthesize the literature published after 2011 on the relationship between 
biomarkers and physical recovery from ischemic stroke. Ultimately, biomarkers may 




PubMed, Embase, and CINAHL databases were searched for studies that 
examined blood biomarkers and functional outcome in patients with ischemic stroke. The 
hierarchical search strategies and keywords were (1) biomarker, (2) ischemic stroke, (3) 
physical recovery, and (4) adult (Supplementary Table 1). Duplications were removed 
from the list, and titles and abstracts of articles retrieved were reviewed for eligibility. All 
relevant articles from reference lists of each reviewed paper were identified. After 
screening the abstracts, final eligibility was determined based on the full content of the 
articles. 
Inclusion and Exclusion Criteria 
Inclusion criteria for the selection of articles to include in the review were: (1) 
primary source of quantitative study in a peer-reviewed journal published in English 
between January 2011 and September 2018; (2) patients ≥ age 18 years diagnosed with 
ischemic stroke; (3) biomarkers measured from blood samples within 24±6 hrs of stroke 




reported the association with physical outcome for each biomarker. Note that the short 
window, within 24±6 hrs for blood sampling relative to stroke onset, maximizes the 
predictive potential of the biomarkers to provide time-sensitive prognostic information in 
the early clinical evaluation of ischemic stroke. Unpublished theses, dissertations, and 
conference proceedings were excluded. 
Study Quality Appraisal  
A code sheet was used to extract information from each article. The information 
included author(s), year of publication, subjects, time frame of blood draw, biomarker(s), 
measurement of physical outcomes, and findings (Cooper, 2017, pp. 110-150). Where 
more than one cohort was examined within a study, the results for each cohort were 
extracted separately. Quality of the study was assessed using the modified questionnaire 
implemented by Whiteley et al. (Whiteley et al., 2009) for the stroke population 
(Supplementary Table 2). These quality components correspond to the sections on study 
design and assay methods sections of the REporting recommendations for tumor 
MARKers prognostic studies (REMARK) (McShane et al., 2005). 
Results 
 Based on the search keywords, 333 studies were identified from PubMed, 
Embase, and CINAHL. Three more studies were found through Google Scholar and 
reference lists of relevant articles. The search procedure (Fig 1) followed the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram 
(Liberati et al., 2009). After screening the title and abstract of each article, 98 full-text 
studies were assessed for eligibility; 18 studies met the eligibility criteria and were 




Characteristics of the Studies 
The articles are listed in ascending chronological order in Supplementary Table 3. 
Studies in this review were published between 2011 and 2018. Sample sizes varied from 
50 to 783 patients. The proportion of male patients was higher than females (54.3% male 
vs. 45.7% female). The overall means of patient ages varied from 59 to 73 years. All 
studies enrolled patients with ischemic stroke, and 5 (28%) included healthy controls as 
clinical comparisons. Only 2 (11%) of the studies selected patients with first-episode 
ischemic stroke; the others did not explicitly address history of stroke. Studies were 
conducted in Spain (7, 39%), Germany (3, 17%), Japan (2, 11%), and 1 (6%) each in the 
Netherlands, Turkey, the United Kingdom, Poland, the United States, and Italy. Of 73 
molecules tested in the 18 studies, 35 (48%) were significantly associated with physical 
recovery after ischemic stroke. 
Methodological Assessment 
 The percentages of reports reviewed that met the modified REMARK criteria for 
methodological quality are shown in Supplementary Table 4 and Figure 2. All study 
authors defined clinical outcome and provided the characteristics of the study population; 
94% used a prospective design; 94% developed a logistic regression model and reported 
such adjustment variables as age and stroke severity; 72% defined enrollment period; and 
67% provided information on the measurement of biomarkers. Few authors reported 
sample size calculation (6%), and blinded biomarker measurement (33%).  
Physical function was defined as an individual's capacity to perform daily 
personal living tasks like eating, walking, and bathing (Ilunga Tshiswaka, Seals, & 




reported (Supplementary Table 3). Various instruments (NIHSS, mRS, or mBI) were 
used and outcomes were measured at different time points after stroke (admission, 1, 3, 
or 6 months). All studies presented NIHSS stroke severity at admission, but only one 
study reported the 3-month NIHSS score. Therefore, in this review, NIHSS score was not 
used to define physical recovery from ischemic stroke. In 15 studies (83%), physical 
outcomes at 3 months were evaluated by mRS or mBI; 2 (11%) and 1 (6%) of the studies 
reported physical outcomes at 1 and 6 months after stroke, respectively. Poor outcome 
was defined according to definitions used in the reviewed articles: mRS ≥ 3 in 13 (72%) 
studies, mRS ≥ 2 in 2 (11%) studies and mBI < 15 in 1 (6%) study; two studies did not 
provide cut-off scores for the mRS. Likewise, for this review, we defined physical 
recovery as used by the authors of the reviewed articles. 
Biomarker Findings 
Biomarkers related to biological functions. The 34 biomarkers that were 
significantly associated with physical outcome after ischemic stroke were divided into 
four categories based on biomarker biological function (Table 1). In terms of immune 
response, patients with lower levels of C-C motif chemokine 11 (CCL11), interleukin 
(IL)-1β and IL-8, and monocyte chemoattractant protein 1(MCP1) and higher levels of 
adiponectin, IL-1Ra, IL-6, IL-10, IL-12, copeptin, C-reactive protein (CRP), growth 
differentiation factor-15 (GDF-15), osteopontin, tumor necrosis factor-alpha (TNFα), and 
white blood cell (WBC) count at stroke onset showed worse physical recovery (poor 
outcomes at 1, 3, or 6 months post-stroke). Notably, patients with poor outcome exhibited 
more than twofold higher levels of copeptin, IL-6, and TNFα compared to those with 




For lipid/metabolism biomarkers, decreased high-density lipoprotein cholesterol 
(HDL-C) and increased cholesterol, low-density lipoprotein cholesterol (LDL-C), and 
glucose at stroke onset were significantly associated with worse functional outcome at 1, 
3, or 6 months post-stroke. With respect to biomarkers of neuronal function, patients with 
ischemic stroke who had higher levels of glutamate and lower levels of glutamic 
oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), and brain-
derived neurotrophic factor (BDNF) tended to have worse outcomes at 1, 3, or 6 months 
after stroke. Patients with poor outcome at 1, 3, or 6 months post-stroke showed 
increased levels of the blood vessel/circulation biomarkers D-Dimer, endostatin, 
fibronectin,  pro-matrix metalloproteinase-10 (proMMP-10), troponin, and midregional 
proatrial natriuretic peptide (MR-proANP) and decreased levels of estimated glomerular 
filtration rate (eGFR), creatinine clearance (CrCl), hematocrit, and hemoglobin at stroke 
onset. Furthermore, elevated levels of fibrinogen at 1 and 3 months after stroke were 
associated with poor outcome.   
Biomarkers related to physical recovery. Among 34 blood biomarkers that 
were significantly associated with physical outcome after ischemic stroke (Table 2), 10, 
26, and 2 biomarkers, respectively, showed a significant association with physical 
outcome at 1, 3, or 6 months following ischemic stroke: 60% (6 of 10) of biomarkers 
predictive of physical outcome at 1 month were classified in the blood vessel/circulation 
category; 54% (14 of 26) of biomarkers that predicted recovery between 3 and 6 months 
post-stroke were related to the immune response. Elevated levels of CRP and fibrinogen 




Low level of CCL11 and high level of blood glucose were significantly associated 
with poor outcome at 3 and 6 months after ischemic stroke. Nine (50%) of the reviewed 
studies reported biomarkers and physical outcomes in patients who had received tissue 
plasminogen activator (tPA) intravenously, the gold standard treatment of acute ischemic 
stroke (Adeoye, Hornung, Khatri, & Kleindorfer, 2011). In this review, patients who 
received tPA treatment with poor physical outcomes compared to those with good 
outcomes had higher levels of IL-6, TNFα, osteopontin, fibronectin, endostatin, 
proMMP-10, CRP, IL-1Ra, IL-10, and IL-12; and lower levels of HDL, BDNF, IL-1β, 
IL-8, and MCP1. 
Discussion 
Of 73 putative biomarkers tested, 34 were found in this review to be statistically 
significantly associated with physical recovery after ischemic stroke. The biomarkers 
showed an association with poor outcome by different instruments (mRS or mBI) and 
measurement time points (admission, 1, 3, or 6 months after stroke). To provide a 
functional view of the biomarkers, we divided the 34 into four categories based on 
biological function of the individual biomarker: immune response, lipids/metabolism, 
neuronal function, and blood vessel/circulation. 
Immune Response 
Brain injury from ischemia is exacerbated by the inflammatory response to cell 
injury and necrosis (Iadecola & Anrather, 2011; Wang et al., 2007). To repair tissue 
damage, inflammatory cytokines and chemokines attract immune cells from the 
circulation into the brain (Lakhan et al., 2009; Simats et al., 2016), and over-activated 




(Dziedzic, 2015; J. Y. Kim et al., 2014). We found that 54% of the 26 biomarkers that 
predicted long-term (3-6 month) stroke recovery are related to immune response. 
Consistently, IL-6 (Gori et al., 2017; Rodriguez et al., 2013), TNFα (Gori et al., 2017; 
Rodriguez et al., 2013), and CRP (De Marchis et al., 2013; De Marchis et al., 2018; Gori 
et al., 2017) were found to be robust predictors of long-term functional outcome in 
ischemic stroke. Therefore, higher levels of immune-related biomarkers after ischemic 
stroke may reflect worse physical recovery. 
Lipids/Metabolism 
We identified four lipid/metabolism biomarkers (high glucose, cholesterol, HDL-
C, and low LDL-C) that were significantly associated with poor outcome after ischemic 
stroke. High blood glucose, cholesterol, and LDL-C and low HDL-C levels have been 
associated with increased risk for atherosclerosis and stroke (Brites, Martin, Guillas, & 
Kontush, 2017; Giacco & Brownlee, 2010; Zhao et al., 2016). LDL-C and hemoglobin 
A1c (HbA1c) levels guide recommendations in the American Heart 
Association/American Stroke Association stroke prevention guidelines (Kernan et al., 
2014). A prior systematic review indicated that low HDL-C level is associated with 
worse physical outcome after ischemic stroke (Amarenco, Labreuche, & Touboul, 2008). 
Five of the articles (Brea et al., 2011; Campos et al., 2011; De Marchis et al., 2013; De 
Marchis et al., 2018; Luitse et al., 2013) reviewed in this paper indicated that 
hyperglycemia was associated with poor outcome in patients with ischemic stroke, which 
is consistent with previous studies (Hasan et al., 2012; Nair, Sylaja, Sreedharan, & 
Sarma, 2017; Putaala et al., 2011). Hasan et al. (Hasan et al., 2012) reported that 




the majority of biomarkers we found associated with physical recovery after treatment 
with tPA were related to immune response and blood vessel/circulation, not to glucose or 
other biomarkers in the lipid/metabolism category.  
Neuronal Function 
Although different brain regions have different thresholds for ischemic cell 
damage, neurons are the most sensitive to hypoxia (Woodruff et al., 2011). Glutamate is 
the major excitatory neurotransmitter in the brain that mediates the signal of neuronal 
degeneration following ischemic stroke (Bano & Nicotera, 2007; Lai, Zhang, & Wang, 
2014). Elevated levels of glutamate, with decreased GOT and GPT (enzymes to decrease 
the level of glutamate in peripheral blood), may induce neuronal apoptosis (Iadecola & 
Anrather, 2011; Teichberg, Cohen-Kashi-Malina, Cooper, & Zlotnik, 2009). Higher 
levels of glutamate, and lower levels of GOT, GPT, and BDNF were associated with less 
favorable physical recovery after ischemic stroke in this review. Hasan et al. (Hasan et 
al., 2012) reported similar findings that elevated glutamate may indicate progressive 
stroke.  
Blood Vessel/Circulation 
Ischemia disrupts the mitochondrial membrane potential, which generates 
excessive reactive oxygen species (ROS) in endothelial cells of cerebral blood vessels 
(Kalogeris, Bao, & Korthuis, 2014). ROS damages mitochondrial DNA, activates the 
inflammatory response, induces secretion of MMPs, and leads to endothelial cell swelling 
and death (Hu et al., 2016). This process triggers breakdown of the blood-brain barrier 




ischemic brain when cerebral blood flow is restored to damaged vasculature), which 
adversely affects stroke outcome.  
Fibrinogen, an acute phase protein, is involved in platelet activation, coagulation, 
and hemostasis (Koenig, 2003). Our results support earlier findings that elevated 
fibrinogen level is associated with poor functional outcome at 1 (Potpara et al., 2014) and 
3 months (Campos et al., 2011) after ischemic stroke. Interestingly, a prior study 
indicated that an early reduction in fibrinogen increases the risk of intracerebral 
hemorrhage after tPA treatment in ischemic stroke patients (Vandelli et al., 2015). 
Therefore, the relationship between fibrinogen and physical outcome among ischemic 
stroke patients, with or without tPA intervention, merits further research. 
Strengths and Weaknesses of the Research 
A strength of this systematic review is the criterion for timing of blood collection 
for biomarker determination. The short window – within 24±6 hrs – for blood sampling 
relative to stroke onset maximizes the predictive potential of the biomarkers to provide 
time-sensitive prognostic information in the early clinical evaluation of ischemic stroke. 
Moreover, because stroke recovery is a chronic process, this review addressed potential 
prognostic prediction of physical recovery at 1, 3, and 6 months after ischemic stroke. 
Categorization of predictive biomarkers into four broad categories based on biological 
function may further inform our understanding of the clinicopathology of stroke. On the 
other hand, the short window for blood collection precluded biomarkers that are 
expressed in the later phases of ischemic stroke, which may have prognostic importance 




high levels of glucose, glutamate, and fibrinogen within 24±6 hrs of stroke onset were 
repeatedly found to be associated with poor outcome after ischemic stroke.   
The review is limited by the information that could not be accounted for because 
it was either not controlled or not reported in the primary source articles. Biomarker 
expression typically follows a circadian rhythm. For example, expression of TNFα, IL-
1β, and IL-6 is known to peak in the evening (Scheiermann, Kunisaki, & Frenette, 2013), 
whereas copeptin level remains unchanged throughout the 24-hour day (Beglinger, 
Drewe, & Christ-Crain, 2017). Unknown biomarker expression pattern and/or 
inconsistency in timing of blood collection within and across studies could have 
adversely affected the findings. Such issues should be addressed in future prospective 
studies on biomarker expression after ischemic stroke. Another limitation is the small 
sample size in some of the eligible studies, which inherently compromises the statistical 
power of the relationships between blood biomarkers and physical recovery from 
ischemic stroke. 
Implications for Clinical Practice and Future Research 
The biomarkers we found in the acute period may provide useful insights into 
prognosis and mechanism(s) of action. These findings can facilitate biomarker-based care 
in patients with ischemic stroke, and thus match patients with appropriate intervention.  A 
robust number and types of biomarkers have been and continue to be investigated in 
patients with ischemic stroke. Biomarkers show promise, especially in the prognosis of 
functional recovery and evaluation of therapeutic response, but the current application of 
their usefulness in practice is elusive without further research evidence from controlled 




levels with phases of physical recovery; the timing may well correlate with the biological 
classification of the biomarker and suggest different pathways that are mechanistically 
different for acute and chronic stroke recovery. For instance, troponin, a blood 
vessel/circulation marker, indicates myocardial damage in acute coronary syndromes; 
patients with higher levels of troponin on admission or a peak of troponin measured 
within 48 hours of a myocardial infarction are likely to have a more difficult and 
prolonged recovery than patients with lower troponin levels (Wettersten & Maisel, 2015).    
Prior studies have shown a circadian rhythm influence on cytokine expression 
(Beglinger et al., 2017; Scheiermann et al., 2013). Because 43% of the identified 
biomarkers in this review are related to immune response; future studies should control 
the time of day the blood is collected for biomarker determination. Finally, the time of 
the blood sample collection was constrained to within 24±6 hrs of stroke onset in this 
review. These early markers may be used in a predictive way to identify subjects at high 
risk for poor recovery beyond the discharge NIHSS and mRS, so they could be targeted 
for more aggressive interventions, Additionally, future investigations may extend the 
time of blood collection to 3 days, 7 days, or even 3 months after stroke to help 
understand how molecules released in the later response phase correlate with physical 
outcome after ischemic stroke.  
Summary/Conclusions 
A systematic review of biomarkers for prediction of stroke recovery has not been 
updated since 2011. In the present review, 34 blood biomarkers were significantly 
associated with physical outcome after ischemic stroke. These biomarkers fall into the 




blood vessel/circulation. The majority of biomarkers appears to predict physical recovery 
at 3 months following ischemic stroke, with fewer biomarkers predictive of recovery at 1 
and 6 months.  
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 Categories of Biomarkers Significantly Associated with Physical Outcome after Ischemic Stroke  
Category Biomarker Article Reference Numbers 
Immune response Adiponectin, CCL11, Copeptin, CRP, GDF-15, IL-
1β, IL-1Ra, IL-10, IL-12, IL-6, IL-8, MCP1, 
Osteopontin, TNFα, WBC 
(Brea et al., 2011; De Marchis et al., 
2013; De Marchis et al., 2018; Gori et al., 
2017; Groschel et al., 2012; Kuwashiro et 
al., 2014; Mendioroz et al., 2011; Potpara 
et al., 2014; Rodriguez et al., 2013; Roy-
O’Reilly et al., 2017) 
Lipids/Metabolism Cholesterol, Glucose, HDL-C, LDL-C (Brea et al., 2011; Campos et al., 2011; 
De Marchis et al., 2013; De Marchis et 
al., 2018; Luitse et al., 2013; Makihara et 
al., 2012; Potpara et al., 2014) 




CrCl, D-Dimer, eGFR, Endostatin, Fibrinogen, 
Fibronectin, Hematocrit, Hemoglobin, MR-
proANP, proMMP-10, Troponin  
(Campos et al., 2011; De Marchis et al., 
2013; De Marchis et al., 2018; Navarro-
Sobrino et al., 2011; Potpara et al., 2014; 
Rodriguez et al., 2013) 
Note. BDNF=Brain-derived neurotrophic factor; CCL11=C-C motif chemokine 11; CrCl=Creatinine Clearance; CRP=C-reactive 
protein; eGFR=Estimated glomerular filtration rate; GDF-15=Growth Differentiation Factor-15; GOT=Glutamic oxaloacetic 
transaminase; GPT=Glutamic pyruvic transaminase; HDL-C=High-density lipoprotein cholesterol; IL=Interleukin; LDL-C=Low-
density lipoprotein cholesterol; MCP1=Monocyte chemoattractant protein 1; MMP=Matrix Metalloproteinase; MR-








Biomarkers Significantly Associated with Physical Outcome after Ischemic Stroke by Time after Stroke. 
Time after 
stroke 
Biomarker associated with physical outcome 
Article Reference 
Numbers 
Immune response Lipids/Metabolism Neuronal function Blood vessel/Circulation  





(Potpara et al., 2014; 
Selçuk et al., 2014) 
3 months Adiponectin, CCL11, 
Copeptin, CRP, GDF-
15, IL-1β, IL-1Ra, IL-
6, IL-8, IL-10, IL-12, 
MCP1, Osteopontin, 
TNFα  
Glucose, HDL-C BDNF, Glutamate, 





(Brea et al., 2011; 
Campos et al., 2011; 
De Marchis et al., 
2013; De Marchis et 
al., 2018; Gori et al., 
2017; Groschel et 
al., 2012; Kuwashiro 
et al., 2014; Lasek-
Bal et al., 2015; 
Makihara et al., 
2012; Mendioroz et 
al., 2011; Navarro-
Sobrino et al., 2011; 
Rodriguez et al., 
2013; Roy-O’Reilly 







6 months CCL11 Glucose     (Luitse et al., 2013; 
Roy-O’Reilly et al., 
2017) 
Note. BDNF=Brain-derived neurotrophic factor; CCL11=C-C motif chemokine 11; CrCl=Creatinine Clearance; CRP=C-reactive 
protein; eGFR=Estimated glomerular filtration rate; GDF-15=Growth Differentiation Factor-15; GOT=Glutamic oxaloacetic 
transaminase; GPT=Glutamic pyruvic transaminase; HDL-C=High-density lipoprotein cholesterol; IL=Interleukin; LDL-C=Low-
density lipoprotein cholesterol; MCP1=Monocyte chemoattractant protein 1; MMP=Matrix Metalloproteinase; MR-





Figure 1. Flow diagram of the literature search. Adapted from “The PRISMA statement 
for reporting systematic reviews and meta-analyses of studies that evaluate healthcare 
interventions: explanation and elaboration” by Liberati, A. and Altman, D. G., 2009, 






Figure 2. Study quality of the 18 articles in the systematic review assessed by the 








Supplementary Table 1 
Search Strategies in PubMed, Embase, and CINAH 
PubMed 
Search strategies  Search keywords  
(1) biomarker ("Chemokines"[Mesh] OR "Cytokines"[Mesh] OR "cytokine"[Text Word] OR "cytokines"[Text Word] OR "chemokine"[Text 
Word] OR "chemokines"[Text Word] OR "Biomarkers"[Mesh] OR "biomarkers"[Text Word] OR "biomarker"[Text Word] OR 
"Immune Markers"[Text Word] OR "Immune Marker"[Text Word] OR "immunologic Markers"[Text Word] OR "immunologic 
Marker"[Text Word] OR "blood biomarker"[Text Word] OR "blood biomarkers"[Text Word] OR "serum biomarker"[Text Word] 
OR "serum biomarkers"[Text Word] OR "plasma biomarker"[Text Word] OR "plasma biomarkers"[Text Word] OR "plasma 
marker"[Text Word] OR "plasma markers"[Text Word] OR "serum marker"[Text Word] OR "serum markers"[Text Word] OR 
"blood marker"[Text Word] OR "blood markers"[Text Word] OR "blood indicator"[Text Word] OR "blood indicators"[Text Word] 
OR "serum indicator"[Text Word] OR "serum indicators"[Text Word] OR "plasma indicator"[Text Word] OR "plasma 
indicators"[Text Word] OR "plasma factors"[Text Word] OR "plasma factor"[Text Word] OR "serum factors"[Text Word] OR 
"serum factor"[Text Word] OR "blood factors"[Text Word] OR "blood factor"[Text Word] OR "biological marker"[Text Word] OR 
"biological markers"[Text Word] OR "biologic marker"[Text Word] OR "biologic markers"[Text Word]) 
(2) ischemic stroke ("Cerebrovascular Disorders"[Mesh] OR "Cerebrovascular Disorders"[Text Word] OR "Cerebrovascular Disorder"[Text Word] OR 
"Cerebrovascular"[Text Word] OR "ischemic stroke"[Text Word] OR "Brain Ischemia"[Text Word] OR "cva"[Text Word] OR 
"ischemic strokes"[Text Word] OR "stroke syndrome"[Text Word] OR "Brain Ischemia"[Mesh] OR "cerebral vascular 
accident"[Text Word] OR "cerebrovascular accident"[Text Word] OR "stroke syndromes"[Text Word] OR "cerebrovascular 
accidents"[Text Word] OR "cerebral vascular accidents"[Text Word] OR "Brain Ischemias"[Text Word] OR "cerebral 







(3) physical recovery ("Recovery of Function"[Mesh] OR "Recovery of Function"[Text Word] OR "function recovery"[Text Word] OR "function 
recoveries"[Text Word] OR "physical recovery"[Text Word] OR "physical recoveries"[Text Word] OR "functional recovery"[Text 
Word] OR "functional recoveries"[Text Word] OR "stroke recovery"[Text Word] OR "motor recovery"[Text Word] OR "motor 
recoveries"[Text Word] OR "Prognosis"[Mesh] OR "Stroke Rehabilitation"[Mesh] OR "Prognosis"[Text Word] OR 
"Prognoses"[Text Word] OR "Stroke Rehabilitation"[Text Word] OR "Stroke Rehabilitations"[Text Word])  
AND 
("severity"[Text Word] OR "disability"[Text Word] OR "mobility"[Text Word] OR "functional independence"[Text Word] OR 
"physical independence"[Text Word] OR "motor function"[Text Word] OR "motor functions"[Text Word] OR “health 
outcome"[Text Word] OR “health outcomes"[Text Word] OR “physical outcomes"[Text Word] OR “physical outcome” [Text 
Word] OR "functional outcomes"[Text Word] OR "functional outcome"[Text Word] OR "motor performance"[Text Word] OR 
"motor performances"[Text Word] OR "physical function"[Text Word] OR "physical functions"[Text Word]) 
(4) adult (“Adult"[Mesh] OR "adult"[Text Word] OR "adults"[Text Word] OR "aged 18 years"[Text Word] OR "age 18 years"[Text Word] 
OR "aged"[Text Word] OR "elderly"[Text Word] OR "aged 65 years"[Text Word] OR "age 65 years"[Text Word] OR 
"Aged"[Mesh] OR "working age"[Text Word] OR "working-age"[Text Word] OR "working aged"[Text Word] OR "working-
aged"[Text Word]) 




Search strategies  Search keywords  
(1) biomarker immune markers':ti,ab,kw OR 'immune marker':ti,ab,kw OR 'immunologic markers':ti,ab,kw OR 'immunologic marker':ti,ab,kw OR 
'blood biomarker':ti,ab,kw OR 'blood biomarkers':ti,ab,kw OR 'serum biomarker':ti,ab,kw OR 'serum biomarkers':ti,ab,kw OR 
'plasma biomarker':ti,ab,kw OR 'plasma biomarkers':ti,ab,kw OR 'plasma marker':ti,ab,kw OR 'plasma markers':ti,ab,kw OR 'serum 
marker':ti,ab,kw OR 'serum markers':ti,ab,kw OR 'blood marker':ti,ab,kw OR 'blood markers':ti,ab,kw OR 'blood indicator':ti,ab,kw 
OR 'blood indicators':ti,ab,kw OR 'serum indicators':ti,ab,kw OR 'serum indicator':ti,ab,kw OR 'plasma indicator':ti,ab,kw OR 
'plasma indicators':ti,ab,kw OR 'plasma factors':ti,ab,kw OR 'plasma factor':ti,ab,kw OR 'serum factor':ti,ab,kw OR 'serum 
factors':ti,ab,kw OR 'blood factors':ti,ab,kw OR 'blood factor':ti,ab,kw OR 'biologic markers':ti,ab,kw OR 'biologic marker':ti,ab,kw 
OR 'cytokine'/exp OR 'cytokine':ti,ab,kw OR 'cytokines':ti,ab,kw OR 'biomarkers':ti,ab,kw OR 'biomarker':ti,ab,kw OR 'biological 








(2) ischemic stroke cerebrovascular disease'/exp OR 'cerebrovascular disorders':ti,ab,kw OR 'cerebrovascular disorder':ti,ab,kw OR 
'cerebrovascular':ti,ab,kw OR 'brain ischemia'/exp OR 'brain ischemia':ti,ab,kw OR 'brain ischemias':ti,ab,kw OR 'ischemic 
stroke':ti,ab,kw OR 'ischemic strokes':ti,ab,kw OR 'cva':ti,ab,kw OR 'stroke syndrome':ti,ab,kw OR 'stroke syndromes':ti,ab,kw OR 
'cerebral vascular accident':ti,ab,kw OR 'cerebral vascular accidents':ti,ab,kw OR 'cerebrovascular accident':ti,ab,kw OR 
'cerebrovascular accidents':ti,ab,kw OR 'brain ischemias':ti,ab,kw OR 'cerebral ischemia':ti,ab,kw OR 'cerebral ischemias':ti,ab,kw 
OR 'ischemic brain':ti,ab,kw OR 'ischemic brains':ti,ab,kw 
(3) physical recovery functional recovery'/exp OR 'prognosis'/exp OR 'stroke rehabilitation'/exp OR 'functional recovery':ti,ab,kw OR 'prognosis':ti,ab,kw 
OR 'stroke rehabilitation':ti,ab,kw OR 'recovery of function':ti,ab,kw OR 'function recovery':ti,ab,kw OR 'function 
recoveries':ti,ab,kw OR 'physical recovery':ti,ab,kw OR 'physical recoveries':ti,ab,kw OR 'functional recoveries':ti,ab,kw OR 'stroke 
recovery':ti,ab,kw OR 'stroke recoveries':ti,ab,kw OR 'motor recovery':ti,ab,kw OR 'motor recoveries':ti,ab,kw OR 
'prognoses':ti,ab,kw OR 'stroke rehabilitations':ti,ab,kw 
AND 
'functional independence':ti,ab,kw OR 'disability':ti,ab,kw OR 'severity':ti,ab,kw OR 'mobility':ti,ab,kw OR 'physical 
independence':ti,ab,kw OR 'motor functions':ti,ab,kw OR 'motor function':ti,ab,kw OR 'health outcome':ti,ab,kw OR 'health 
outcomes':ti,ab,kw OR 'physical outcomes':ti,ab,kw OR 'physical outcome':ti,ab,kw OR 'functional outcomes':ti,ab,kw OR 
'functional outcome':ti,ab,kw OR 'motor performance':ti,ab,kw OR 'motor performances':ti,ab,kw OR 'physical function':ti,ab,kw 
OR 'physical functions':ti,ab,kw 
(4) adult adult'/exp OR 'aged'/exp OR 'adult':ti,ab,kw OR 'adults':ti,ab,kw OR 'aged':ti,ab,kw OR 'elderly':ti,ab,kw OR 'aged 18 
years':ti,ab,kw OR 'age 18 years':ti,ab,kw OR 'aged 65 years':ti,ab,kw OR 'age 65 years':ti,ab,kw OR 'working age':ti,ab,kw OR 
'working-age':ti,ab,kw OR 'working aged':ti,ab,kw OR 'workingaged':ti,ab,kw 




Search strategies  Search keywords  
(1) biomarker (MH "Biological Markers") OR "Biomarkers" OR "Biomarker" OR "Immune Markers" OR "Immune Marker" OR "immunologic 
Markers" OR "immunologic Marker" OR "blood biomarker" OR "blood biomarkers" OR "serum biomarker" OR "serum 
biomarkers" OR "plasma biomarker" OR "plasma biomarkers" OR "plasma marker" OR "plasma markers" OR "serum marker" OR 
"serum markers" OR "blood marker" OR "blood markers" OR "blood indicator" OR "blood indicators" OR "serum indicator" OR 
"serum indicators" OR "plasma indicator" OR "plasma indicators" OR "plasma factors" OR "plasma factor" OR "serum factor" OR 
"serum factors" OR "blood factors" OR "blood factor" OR "biological marker" OR "biological markers" OR "biologic markers" OR 








(2) ischemic stroke MH "Cerebrovascular Disorders" OR "Cerebrovascular Disorders" OR "Cerebrovascular Disorder" OR "Cerebrovascular" OR 
"ischemic stroke" OR "Brain Ischemia" OR "cva" OR "ischemic strokes" OR "stroke syndrome" OR "cerebral vascular accident" 
OR "cerebrovascular accident" OR "cerebrovascular accidents" OR "stroke syndromes" OR "cerebral vascular accidents" OR (MH 
"Cerebral Ischemia") OR "Brain Ischemias" OR "cerebral ischemia" OR "cerebral ischemias" OR "ischemic brain" OR "ischemic 
brains"  
(3) physical recovery "Recovery of Function" OR "function recovery" OR "function recoveries" OR "physical recovery" OR "physical recoveries" OR 
"functional recovery" OR "functional recoveries" OR "stroke recovery" OR "motor recovery" OR "motor recoveries" OR MH 
"Prognosis" OR "Prognosis" OR "Prognoses" OR "Stroke Rehabilitation" OR "Stroke Rehabilitations"  
AND 
"severity" OR "disability" OR "mobility" OR "functional independence" OR "physical independence" OR "motor function" OR 
"motor functions" OR "health outcome" OR "health outcomes" OR "physical outcome" OR "physical outcomes" OR “functional 
outcomes” OR “functional outcome” OR “motor performance” OR “motor performances” OR “physical function” OR “physical 
functions” 
(4) adult (MH "Adult") OR "Adult" OR "adults" OR (MH "Aged") OR "Aged" OR "aged 18 years" OR "age 18 years" OR "elderly" OR 
"aged 65 years" OR "age 65 years" OR "working age" OR "working-age" OR "working aged" OR "working-aged"  








Supplementary Table 2 
REMARK Quality Questionnaire 
Item Yes No 
1 Was the study prospective?   
 YES: The study reported that patients and blood samples were collected prior to the development of an outcome   
 NO: No report or clearly retrospective (e.g. patients with poor prognosis collected prior to biomarker measurement)   
2 Was the evaluation of prognostic marker blinded to patient outcome?   
 YES: The study reported an attempt to blind the person measuring the level of biomarker to patient outcome   
 NO: There was no such report   
3 Was there a defined time period during which patients were enrolled?   
 YES: Study defined time period, end of follow up period and median follow up time   
 NO: Did not define above criteria   
4 Were there precisely defined clinical outcomes at the beginning of the study?   
 YES: Study defined which clinical endpoints are to be measured   
 NO: No such definition   
5 Did the study provide a rationale for study sample size?   
 YES: Evidence of a sensible sample size calculation   
 NO: No attempt to define sample size   
6 Did the study provide a list of candidate variables?   
 
YES: A list of variables to be considered in multiple regression analysis were provided at the beginning of the study 
  
 NO: Evidence that variables measured and not reported   




 NO   
8 Were the characteristics of the study patients described?   
 
YES: The study described the source and inclusion and exclusion criteria. 
  







Note. REMARK= REporting recommendations for tumour MARKer prognostic studies. Modified from “Blood markers for the 








Supplementary Table 3 












(mean ± SD) 
Blood biomarkers 
Outcome measures  
(time point) Results: blood biomarker levels 




































1h, 2h, 12h, 
24h, 48h and 
discharge) 
1. Higher endostatin is associated 
with poor outcome (mRS≥3). 
2. Lower KGF/endostatin, 
KGF/TSP-1, and VEGF-R2/TSP-
1 are associated with worse 
severity (admission). 
3. Lower KGF/TSP-1 and VEGF-
R2/TSP-1 are associated with 
worse severity (1h). 





R2/TSP-1, and HGF/Angiostatin 
are associated with worse severity 
(2 and 12h). 
5. VEGF, PDGF-BB/Angiostatin, 
PDGF-AA//TSG-1, 
VEGF/endostatin, and 
HGF/Angiostatin are associated 
with worse severity (24h). 
6. VEGF, PDGF-BB/Angiostatin, 
and VEGF/endostatin are 
associated with worse severity 
































1. Higher osteopontin is associated 
with poor outcome (mRS≥3). 
2. No relationship between glucose 
and stroke disability (mRS≥3). 
3. No relationship between 
osteopontin and stroke severity. 
Brea et al., 
2011(Brea 


























24h, 72h, 7 
days, 3M) 
1.  Higher glucose and CRP are 
associated with poor outcome 
(mRS≥3). 
2. TLR3,7,8, and 9 are not 




os et al., 
2011) 
Spain 

















1. Higher glucose, fibrinogen, and 
blood glutamate are associated 
with poor outcome (mRS≥3). 
2. Lower GOT and GPT are 






















1. Higher GDF-15 is associated with 
poor outcome (mRS≥2). 































1. Lower HDL-C is associated with 






















1. Neither Lp-PLA2 mass or Lp-
PLA2 activity is not associated 
with stroke severity. 
2. No differences were found in 
either Lp-PLA2 mass or activity 










(with vs without 
tPA) 




















1. proMMP-10, C-Fibronectin, IL-6, 
and TNFα are significantly higher 
in tPA treated patients with poor 
outcome (mRS≥3).*proMMP-10 
is significantly higher in non-tPA 

























1. Hyperglycemia is associated with 
poor outcome (mRS≥3). 
2. Hyperglycemia is associated with 




































1. Higher copeptin, glucose, and 
CRP are associated with poor 
outcome (mRS≥3). 

















1. The first day S100B level is not 
associated with post-stroke 
disability at 1 month. 
2. There was a poor correlation 
between functional outcome at 1-
month post-stroke and the third 
day S100B level.  
3. No correlation between stroke 




ra et al., 
2014) 















1. Higher CRP, fibrinogen, cardiac 
Tnl, D-dimer, WBC, LDL, and 
total cholesterol are associated 
with poor outcome (mRS≥3). 
2. Lower CrCl and hematocrit are 























1.  Higher adiponectin is associated 



















1. ChT activity is not related to 
baseline stroke severity. 
2. Higher ChT activity is associated 
with poor outcome (mRS≥3), but 



















1. Lower BDNF is associated with 


















1.  Lower CCL11 is associated with 
poor outcome at 3 months 








Gori et al., 
2017(Gori 

























MMP1, 2, 3, 7, 8, 
and 9  





1. CRP, IL-1β, IL-1Ra, IL-6, IL-
8.IL-10, IL-12, TNFα, and MCP1 
(Pre-post tPA) were associated 




























1. Higher MR-proANP, glucose, and 
CRP are associated with poor 
outcome (mRS≥3). 
2. Lower eGFR is associated with 
poor outcome. 
Note. * indicates statistically significant difference; A2M=Alpha-2-Macroglobulin; BDNF=Brain-derived neurotrophic factor; 
CCL11=C-C motif chemokine 11; ChT=Chitotriosidase; CrCl = Creatinine Clearance; CRP = C-reactive protein; eGFR = Estimated 
glomerular filtration rate; GDF-15 = Growth Differentiation Factor-15; GOT=Glutamic oxaloacetic transaminase; GPT=Glutamic 
pyruvic transaminase; h=hour(s); HDL-C=High-density lipoproteins cholesterol; HG=Hyperglycaemia; HGF=Hepatocyte growth 
factor; IFNγ=Interferon gamma; IL=Interleukin; IP10=Interferon gamma-induced protein 10; KGF=Keratinocyte growth factor; LDL-
C=Low-density lipoproteins cholesterol; Lp-PLA2=Lipoprotein-associated phospholipase A2; M=month(s); mBI= modified Barthel 
index;  MCP1=Monocyte chemoattractant protein 1; MIP1β=Macrophage inflammatory protein-1β; MMP=Matrix Metalloproteinase; 







Institutes of Health Stroke Scale; PDGF=Derived growth factor; S100B=S100 calcium-binding protein B; SAP=Serum amyloid P-
component; SD=Standard deviation; SDF-1=Stromal cell-derived factor-1; TIMP-1=Tissue inhibitor of matrix metalloproteinases-1; 
TLR=Toll-like receptor; TNFα=Tumor necrosis factor-alpha; TnI=Troponin I; tPA=Tissue plasminogen activator; TSG-1=Tumor 
necrosis factor-inducible gene-1; TSP-1=Thrombospondin-1; VEGF=Vascular endothelial growth factor; W=week(s); WBC=White 








Supplementary Table 4 
Quality Assessment of Each Study Included in the Systematic Review by Using the Modified REMARK Questionnaire 
Article 
Item of REMARK questionnaire  
Percentage of 
Yes 
1 2 3 4 5 6 7 8  
(Navarro-Sobrino et al., 2011) Yes No No Yes No Yes Yes Yes 62.5 
(Mendioroz et al., 2011) Yes Yes Yes Yes No Yes Yes Yes 87.5 
(Brea et al., 2011) Yes Yes Yes Yes No Yes Yes Yes 87.5 
(Campos et al., 2011) Yes No No Yes No Yes No Yes 50.0 
(Groschel et al., 2012) Yes Yes Yes Yes No Yes No Yes 75.0 
(Makihara et al., 2012) No No Yes Yes No Yes No Yes 50.0 
(Delgado et al., 2012) Yes No No Yes No Yes Yes Yes 62.5 
(Luitse et al., 2013) Yes No Yes Yes No Yes No Yes 62.5 
(De Marchis et al., 2013) Yes Yes Yes Yes No Yes Yes Yes 87.5 
(Rodriguez et al., 2013) Yes Yes No Yes Yes Yes Yes Yes 87.5 
(Selçuk et al., 2014) Yes No Yes Yes No No Yes Yes 62.5 
(Potpara et al., 2014) Yes No No Yes No Yes Yes Yes 75.0 
(Kuwashiro et al., 2014) Yes No Yes Yes No Yes Yes Yes 75.0 
(Bustamante et al., 2014) Yes Yes Yes Yes No Yes Yes Yes 87.5 
(Lasek-Bal et al., 2015) Yes No Yes Yes No Yes No Yes 62.5 
(Roy-O’Reilly et al., 2017) Yes No Yes Yes No Yes No Yes 62.5 







(De Marchis et al., 2018) Yes No Yes Yes No Yes Yes Yes 75 
Percentage of Yes 94.4 33.3 72.2 100.0 5.6 94.4 66.7 100.0   
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Objective: Post-stroke inflammation is detrimental to the brain and results in an 
unfavorable recovery. Optimism has been associated with lower inflammation and better 
health outcomes among people with medical conditions, but no studies have assessed this 
association in the stroke population. The overall goals were to examine the relationships 
among optimism, stroke severity, physical disability, and inflammation during 
hospitalization and evaluate the relationships among optimism, inflammation, and stroke 
recovery over the three-month post-stroke period.  
Methods: This study was a secondary analysis of data prospectively collected from the 
BioRepository of Neurological Diseases biobank. Outcomes included optimism, stroke 
severity, physical recovery, and inflammatory markers (IL-6, TNF-α, and CRP). 
Spearman’s correlation, Wilcoxon signed-rank test, multiple linear regression, and 
mixed-effect regression model were used to determine the relationships among the 
variables.  
Results: A total of 49 subjects at baseline, with 13 at 3-month follow-up were recruited. 
The results indicated that subjects with higher optimism showed less stroke impairment 
and lower level of CRP at baseline compared to those with lower optimism. Additionally, 
optimism was associated with less stroke severity and lower IL-6 and CRP levels over the 
first three months after stroke.  
Conclusion: Optimistic stroke survivors showed lower inflammation and better stroke 
recovery. By understanding this relationship may provide a scientific framework whereby 
new strategies for stroke recovery can be developed in the future. 




Acronyms: LOT-R = revised Life Orientation Test; NIHSS = National Institutes of 
Health Stroke Scale; mRS = modified Rankin Scale; IL-6 = Interleukin 6; TNF-α = 






Stroke is the 5th leading cause of death in the U.S., with an annual incidence of 
approximately 795,000 cases (Benjamin et al., 2019). Ischemic stroke accounts for 87% 
of all strokes. The most common neurological disease in the adult population worldwide, 
stroke is now the primary cause of long-term adult disability (Feigin et al., 2017); up to 
74% of stroke survivors are dependent in activities of daily living (Miller et al., 2010). 
Motor impairment, sensory dysfunction, and dysphasia are common manifestations of 
stroke. Approximately 30% of stroke survivors in the U.S. suffer permanent disability, 
and 20% of survivors require inpatient rehabilitation within three months after stroke 
(Creutzfeldt et al., 2012).  
Improvements in acute stroke care have reduced stroke-related mortality over the 
past two decades. However, the increased survival rate leaves many survivors living with 
severe disability, placing a tremendous burden on their caregivers and the healthcare 
system (F. Mu et al., 2017). Post-stroke rehabilitation is a continuum, starting within days 
of stroke onset and ending only when it no longer produces any positive effect. Physical 
recovery includes motor function, sensation, language and swallowing ability (Harvey, 
2015). Prior studies indicated that 48 - 91% of physical recovery occurred within the first 
three months after stroke (Lee et al., 2015; Stinear, 2017; Wade et al., 1985). 
Ischemic stroke caused by blood vessel blockage results in cell damage and/or 
cell death. These damaged cells may evoke a massive upregulation of pro-inflammatory 
cytokines, such as interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and C-
reactive protein (CRP), which attract infiltration of innate immune cells from the 




et al., 1999; Lakhan et al., 2009; Simats et al., 2016). Even though the initial immune 
response is to facilitate repair and regeneration of the damaged tissue, the infiltrated 
immune cells may produce cytotoxic mediators that prolong the inflammatory response, 
exacerbate brain damage, and contribute to edema formation and hemorrhagic 
transformation (Hu et al., 2016). These secondary complications commonly influence 
stroke outcomes and leave an individual with residual impairment of physical, 
psychological, and cognitive functions. Hence, properly regulating post-stroke 
inflammation may be a therapeutic strategy to reduce secondary brain injury and enhance 
post-stroke recovery (Simats et al., 2016). 
Optimism is conceptually defined as positive expectations of the future (Scheier 
& Carver, 1985). It is considered a personality trait and a positive psychological factor 
(Conversano et al., 2010a; Scheier & Carver, 1985). Studies have shown that optimism 
may change over time or during situational changes, such as in times of high stress 
(Atienza et al., 2004; Segerstrom, 2007). A meta-analysis indicated that psychological 
intervention approaches such as Best Possible Self (BPS) or cognitive-behavior therapy 
(CBT) might significantly augment optimism levels among various populations (Malouff 
& Schutte, 2017). 
Accumulated studies have found that optimism improves both mental and 
physical health outcomes. For example, optimistic people have reported greater resilience 
to stress, better recovery after cardiac bypass surgery, and improved functional outcomes 
after traumatic brain injury (Ramanathan et al., 2011; Ronaldson et al., 2014; Tindle et 
al., 2012). Additionally, inflammation is prevalent after critical illness and is associated 




discharge (Griffith et al., 2016). Optimism has been linked to lower levels of chronic 
inflammation in older adults (Ikeda et al., 2011) and less blood pro-inflammatory 
cytokines, such as IL-6, CRP, and fibrinogen, in patients with cardiovascular disease 
(Roy et al., 2010).  
A qualitative study found that optimistic stroke survivors may exhibit more 
confidence to face the challenges of stroke recovery (Jones et al., 2008). Moreover, a 
recent study, in which the online survey was conducted by 176 stroke survivors, also 
showed that up to 41 years since diagnosis of stroke, the survivors with higher levels of 
optimism reported fewer depressive symptoms and better perceived overall health 
compared to those with lower levels of optimism (Shifren & Anzaldi, 2018b). However, 
no studies have examined the links among optimism, inflammation, and physical 
recovery in the stroke population. 
The purpose of this study is to examine the relationship among optimism, 
inflammation, and physical recovery in the stroke population. Given the evidence of 
associations among optimism, inflammation, and physical health in multiple other 
diseases, but not stroke, determining how optimism associated with inflammation and 
post-stroke recovery is important. Understanding the mechanisms underlying the role of 
optimism in post-stroke inflammation and physical recovery could allow for the 
development of psychological interventions for boosting optimism. The specific aims and 
hypotheses of this study were:  (1) Examine the relationships among optimism, stroke 
severity, physical disability, and inflammation during hospitalization. It was hypothesized 
that stroke patients with higher levels of optimism during hospitalization would have 




compared to those with lower optimism levels. (2) Examine the longitudinal relationships 
among optimism, inflammation, and stroke recovery at three months post-stroke. It was 
hypothesized that patients’ levels of optimism would remain stable over the three months, 
and more optimistic patients will have less inflammation and accelerated stroke recovery 
over the 3-month post-stroke period compared with less optimistic patients. 
Materials and Methods 
Study Design 
This pilot study was a secondary analysis of data prospectively collected from the 
BioRepository of Neurological Diseases (HSCMH-17-0452, Appendix A). A quantitative 
observational design with repeated measures was used.  
Study Sample 
The sample was selected from consecutive acute stroke subjects admitted to the 
Memorial Hermann Southwest Hospital from June 2018 to January 2019. To investigate 
the relationships among optimism, stroke severity, physical disability, and inflammation 
over a three-month post-stroke period, this study included subjects who were: (1) 18 
years or older; (2)  diagnosed with an ischemic stroke. Subjects were excluded if they (1) 
were diagnosed with transient ischemic attack or intracerebral hemorrhage, including 
secondary hemorrhage on control computed tomography or magnetic resonance imaging 
(to avoid confounding effects of hematoma-induced inflammation); (2) had underlying 
vascular lesions or traumatic brain injury, systemic malignancy, autoimmune disease, or 
immunosuppression use of any immunosuppressive drugs (defined as the use of 






 Optimism. The main predictor variable was the level of optimism, which was 
measured via the LOT-R (Appendix C) (Scheier et al., 1994). Scores on the LOT-R range 
from 0 to 24, with higher scores indicating higher levels of optimism. It includes 10 
items, four of which are filler items that were not used in scoring. Of the six items that 
were scored, three are keyed in a positive direction (1, 4, and 10) and three in a negative 
direction (3, 7, and 9). The respondents indicate the extent to which they agree with each 
item on a 5-point Likert scale that ranges from strongly disagree to strongly agree. 
Internal consistency of the LOT-R was reported α = 0.82 (Shifren & Anzaldi, 2018b) in 
the stroke population and stability (test-retest reliability) over 4 months in college 
students was reported as r = 0.79 (Scheier et al., 1994). Cronbach’s alpha in this study 
was 0.72. Stability over the 3-month period was r = 0.79 (p = 0.001). In order to make 
appropriate comparisons and fully explore the effects of optimism and pessimism on 
stroke severity, physical disability, and inflammatory factors, three partly overlapping 
measures were developed: full scale with six items (LOT-R), optimism subscale with 
three items (OPT), and pessimism subscale with three items (PESS). The higher values 
indicate more positive orientation on LOT-R and OPT and more negative orientation on 
PESS.  
Clinical outcomes. Stroke severity was evaluated via the NIHSS (Appendix D) 
by a certified neurologist  (Brott et al., 1989). Scores on the NIHSS range from 0 to 42, 
with lower scores indicating less impairment. The acceptable interrater reliability was 
reported as an intraclass correlation coefficient of 0.82 (Goldstein & Samsa, 1997) and 




stroke was defined according to the mRS (Appendix E) by a certified neurologist (Banks 
& Marotta, 2007). Scores on the mRS range from 0 to 6, with lower scores indicating less 
disability. The acceptable internal consistency of mRS was reported as Cronbach’s α of 
0.89 in stroke survivors (Wei et al., 2015).  
 Inflammatory markers. Peripheral blood samples were obtained from subjects 
at baseline and 3-month after stroke. Plasma was separated by centrifugation at 1,000-
2,000xg for 10 minutes, aliquoted and stored at −80°C until used. Samples were coded 
and assayed in a blind manner regarding the subjects’ level of optimism, stroke severity 
(NIHSS), and physical disability (mRS). Levels of IL-6, TNF-α, and CRP were measured 
from plasma samples using enzyme-linked immunosorbent assay (ELISA) kits (D6050, 
HSTA00E, and DCRP00; R&D Systems, Minneapolis, MN). The assay sensitivity has 
been reported to be 0.7 pg/mL for IL-6, 0.049 pg/mL for TNF-α, and 0.022 ng/mL for 
CRP. Intra- and inter-assay percent coefficients of variation have been shown between 
2.0% and 6.5%, indicating a high sensitivity and precision. In this study, the intra- and 
inter-assay percent coefficients of variation of IL-6, TNF-α, and CRP were less than 
4.5%.  
Data Collection 
Data were obtained at baseline and 3-month follow-up visit, including LOT-R, 
NIHSS, mRS, IL-6, CRP, and TNF-α. At baseline, subjects’ demographic and clinical 
data, including age, gender, race/ethnicity, medical history, and social support (Need of 
Support and Service Questionnaire, NSSQ) were extracted from the BioRepository 
dataset. Researchers provided up to three telephone reminders in a week before and after 




extracted. Identifiers were restricted to the medical record number, and this unique code 
was used to identify the patients in the data collection sheet based solely on their age, 
gender, and diagnosis of ischemic stroke. This study was approved by the UTHealth 
Committee for the Protection of Human Subjects (HSC-MS-18-0534, Appendix B).  
Sample Size Determination 
For Aim 1, we assumed that the minimum correlation coefficient between 
optimism and stroke severity, physical disability, and inflammation was 0.4 (Ikeda et al., 
2011; Roy et al., 2010). To achieve a correlation coefficient with 80% power at type I 
error of 0.05, we would need 46 patients (Bujang & Baharum, 2016). For Aim 2, we 
planned to compare the outcomes of stroke recovery and inflammation between 
optimistic and non-optimistic groups. Based on related articles and our preliminary data, 
we assumed that the mean differences will be 8.2 with a standard deviation (SD) of 8.1 
(effect size of 1.01) for scores on the NIHSS, 2.3 with a SD of 1.7 (effect size of 1.35) for 
scores on the mRS, and 1.8 with a SD of 2.2 (effect size of 0.82) for CRP levels. The 
required sample sizes for the three variables were 24, 14, and 36, respectively, to achieve 
80% power at a type I error of 0.05 using longitudinal data analysis with a within-subject 
correlation of 0.5 (Hedeker et al., 1999).    
Data Analysis 
Statistical analyses were performed using SPSS for Windows, version 25.0 (SPSS 
Inc., Chicago, IL, USA). Descriptive statistics were used to analyze demographic 
characteristics and clinical history. Kolmogorov–Smirnov tests were performed to assess 
normality distributions in continuous variables. Correlations between numeric variables 




performed to model functional outcomes at baseline on variables (age, sex, race/ethnicity, 
and social support) one by one. Variables with a p-value less than 0.1 were then included 
in multiple linear models as confounders in evaluating the effect of optimism on baseline 
functional outcomes. To compare levels of optimism and other clinical outcomes between 
baseline and 3-month after stroke, Wilcoxon signed-rank test for related samples were 
used. Finally, a linear mixed regression model was used to evaluate the effect of 
optimism on functional outcomes and cytokine levels along the time, adjusted for 
possible confounders. Values of p less than 0.05 were considered statistically significant. 
To adjusting the missing data, in the linear mixed model, a subject with one-time point 
missing did not be dropped from the entire analysis. The remaining data were retained. 
No imputation procedure had been applied. 
Results 
The study group consisted of 49 subjects at baseline and 13 at 3-month follow-up. 
Demographic and baseline characteristics of the subjects are shown in Table 1. Most 
subjects were African American men who had hypertension. 
Table 2 shows the sample means of each variable. The LOT-R scale was scored 
using total score (LOT-R), optimism subscale (OPT), and pessimism subscale (PESS) 
approach. The LOT-R scores in this sample were ranged from 8 to 24 with a mean of 
17.3 ± 4.2. There was no significant difference in the sample mean for the LOT-R scores 
between men (16.6 ± 4.0) and women (18.3 ± 4.4). However, the mean of LOT-R scores 
among Asian (12.3 ± 2.4) was significantly lower than those among whites (17.1 ± 3.9, 
p=0.02) and African American (20.1 ± 3.4, p<0.001). Looking at OPT and PESS as 




PESS. Similarly, no gender difference was observed in the sample means for the OPT 
and PESS subscales. Asian (8.0 ± 1.3, p=0.001) and Hispanics (6.9 ± 3.4. p=0.006) 
showed significantly higher means of the PESS subscale than African American (2.5 ± 
2.8). 
For specific aim 1, it was hypothesized that stroke subjects with higher levels of 
optimism at baseline will have lower levels of stroke severity, physical disability, and 
pro-inflammatory cytokines compared to those with lower optimism levels. In this study, 
49 subjects were collected and reached the planned sample size for this aim. Full results 
of correlation analyses depicted in Table 3. As expected, the level of optimism (LOT-R) 
was positively correlated with OPT subscale (ρ= 0.57, p<0.001), but negatively 
correlated with PESS subscale (ρ= -0.88, p<0.001). LOT-R were also found negatively 
correlated with stroke severity (NIHSS; ρ= -0.41, p=0.003), physical disability (mRS; ρ= 
-0.30, p=0.05), and inflammatory markers IL-6 (ρ= -0.44, p=0.008) and CRP (ρ= -0.40, 
p=0.02), but not with TNF-α. Furthermore, higher scores on OPT subscale were 
significantly associated with lower levels of NIHSS (ρ= -0.31, p=0.03) and CRP (ρ= -
0.48, p=0.004). Higher scores on PESS subscale were also significantly associated with 
higher levels of NIHSS (ρ= 0.33, p=0.02), mRS (ρ= 0.32, p=0.03), and IL-6 (ρ= 0.50, 
p=0.002). However, neither LOT-R nor OPT and PESS subscales showed a clear relation 
pattern with the level of TNF-α. 
After performing univariate regression analyses for different outcomes on each 
independent variables, the variables (age, NSSQ, NIHSS, and mRS) with a p-value less 
than 0.1 were included in multiple linear regression models (Table 4). After adjusting the 




optimism. For every one unit increase of LOT-R, subject’s NIHSS scores will decrease 
0.27 point (p=0.001), mRS will decrease 0.11 point (p=0.03) , and level of CRP will 
decrease 148.6 ng/ml (p=0.02). Nevertheless, levels of IL-6 and TNF-α did not show a 
clear relationship with LOT-R at baseline in the regression model. 
For specific aim 2, it was hypothesized that subjects’ levels of optimism would 
remain stable over the three months, and more optimistic subjects will have less 
inflammation and accelerated stroke recovery over the 3-month post-stroke period 
compared with less optimistic subjects. For this aim,  based on two groups comparison 
within longitudinal data analysis, the planned sample sizes for NIHSS, mRS, and CRP 
levels were 24, 14, and 36, respectively. However, only 13 subjects were successfully 
obtained. Therefore, instead of classifying the subjects into optimistic and non-optimistic 
groups, the optimism scores (LOT-R) were analyzed as a continuous variable to increase 
the power. Based on the result in Table 5, the effect sizes of NIHSS, mRS, and CRP were 
3.83, 1.75, and 2.07, respectively. Using these effect sizes, the required sample sizes for 
the three variables are 9, 12, 11 to achieve a power of 80% with a type I error of 0.05.    
Table 5 shows the means of each variable at baseline and 3-month. Wilcoxon 
signed-rank test was conducted to evaluate the difference between baseline and 3-month 
among the 13 subjects. Levels of NIHSS, mRS, IL-6, and CRP at 3-month were 
significantly lower than those at baseline. TNF-α did not exhibit any significant change. 
Similar to the previous study (Scheier et al., 1994), levels of LOT-R, OPT, and PESS 
remained stable during the three-month post-stroke period.  
Additionally, to adjust the informative attrition, a linear mixed model was 




and CRP, were analyzed as time-varying variables with two observations. Using 
univariate linear mixed models, the results indicated that lower levels of NIHSS, mRS, 
IL-6, and CRP associated with higher LOT-R scores over time. After adjusting for age, 
NIHSS, and mRS, LOT-R was negatively correlated with NIHSS over three-month post-
stroke period (Table 6A, coefficient= -0.23, 95% CI: -0.36 to -0.11), but not mRS 
(coefficient= -0.07, 95% CI: -0.16 to 0.01). The subjects with a higher level of LOT-R 
showed lower levels of IL-6 and CRP over three-month follow-up (Table 6B, 
coefficient= -0.79 and -116.5; 95% CI: -1.33 to -0.25 and -230.95 to -2.05, respectively). 
Discussion 
In this study, 49 ischemic stroke subjects at baseline with 13 at 3-month follow-up 
visit present three key findings. First, optimism was significantly associated with reduced 
stroke severity, less physical disability, and lower level of plasma CRP at baseline while 
controlling for relevant medical and demographic factors. Second, subjects’ levels of 
optimism remained stable over the three months. This finding parallels previous research 
in college students (Scheier et al., 1994). Third, after adjusting relevant factors, optimism 
was significantly associated with lower levels of IL-6 and CRP and improved stroke 
severity over the 3-month post-stroke period. However, there were no significant 
associations found between circulating expression level of TNF-α and optimism at 
baseline and 3-month post-stroke. 
 The findings support recent studies on optimism and overall health in stroke 
survivors. Stroke survivors with higher scores on optimism reported less physical illness 
and depressive symptoms which might improve rehabilitation and recovery after stroke 




2018b). Consistently, higher levels of IL-6 and CRP were associated with lower levels of 
optimism in patients with cardiovascular disease and post-stroke depression (Roy et al., 
2010; Wen, Weymann, Wood, & Wang, 2018).  
 The present study found that levels of CRP at both baseline and 3-month follow-
up were significantly positively associated with the level of optimism among stroke 
subjects. Similarly, prior studies indicated that the level of CRP in patients with post-
stroke depression (PSD) was significantly increased compared to those in patients 
without PSD (Cheng, Tu, Shen, Zhang, & Ji, 2018; Y. Mu, Wang, Zhou, Tan, & Wang, 
2018). Additionally, ischemic stroke patients with a high CRP measured at admission 
associated with more severe stroke, poor functional outcome, and higher mortality 
(Idicula, Brogger, Naess, Waje-Andreassen, & Thomassen, 2009). At present, most of the 
studies reported on CRP values related prognosis and diagnosis of ischemic stroke were 
from the Asian population (Yu et al., 2017). However, no significant difference in the 
CRP levels among the ethnic groups was found in this study.   
Limitations 
There are some potential limitations to the current study. First, the sample size at 
the 3-month follow-up visit was relatively small (n=13). The small sample size might 
have decreased statistical power. However, the changes of CRP from baseline to 3-month 
has an effect size higher than expected and still achieve a statistical significance. 
Unreachable telephone number from medical records, unwilling to continue participating 
in the research project, and moving into nursing home were the primary factors 
contributed to the high attribution rate. To improve patient retention, we may (1) request 




gift cards or transport vouchers; and (3) increase patient engagement, for example, learn 
patients’ and caregiver’s story and share current health data through culture-centered 
approach (Bernstein & Feldman, 2015; Domecq et al., 2014). 
Second, this was a single center study performed in an educational hospital, so the 
findings might not be reflective of the general stroke population. Therefore, the findings 
may need to be validated in a large multicenter cohort study in the future. Third, subjects 
with a preexisting physical disability were not excluded from this study. It might lead to 
misjudgment of the stroke recovery.    
Implications for Practice and Research 
 According to the results, we suggest assessing patients’ level of optimism during 
hospitalization. Clinicians may provide an early follow-up to monitor post-stroke 
recovery for patients with lower level of optimism. Furthermore, an optimistic attitude 
can be induced by manipulating the brain’s physiological activity in a way that 
selectively enhances activity in one hemisphere, such as CBT, BPS, or exercise which 
can significantly enhance subjective and psychological well-being and reduce depressive 
symptoms (Bolier et al., 2013; Meevissen, Peters, & Alberts, 2011). Therefore, clinicians 
can recommend CBT, BPS or exercise to their patients with low levels of optimism. 
Depression is characterized by overly pessimistic thought and a negative-thinking 
style (Hecht, 2013). Over one-third of stroke patients developed post-stroke depression 
(Hackett & Pickles, 2014). Therefore, future studies could longitudinally examine the 
relationships  between optimism, depression, and coping strategies in stroke patients. 
Developing and evaluating appropriate psychological interventions to boost optimism 




be important to examine at which time point after stroke it would be most beneficial for 
patients to receive these interventions.  
Conclusions 
Stroke survivors with a higher level of optimism showed lower inflammation and 
better stroke recovery. A large cohort with a comprehensive analysis is necessary to 
determine the exact role and biological mechanism of optimism in stroke recovery. It is a 
worthwhile endeavor to investigate an effective therapeutic strategy by boosting the level 
of optimism among stroke survivors in the future.  
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Demographic and characteristics of patients with ischemic stroke at baseline (n=49) 
Characteristics Subjects 
Age, years, Mean (S.D.) 59.29 (14.09) 
Sex, male, n (%) 28 (57.1) 
Race/ethnicity, n (%) 
    White 
    African American 
    Hispanics 






Risk factors, n (%) 
History of stroke 
TIA 





















Note. S.D., Standard deviation; TIA, Transient ischemic attack; A-fib, Atrial fibrillation; 














The levels of variables at baseline 
Variables n 




   LOT-R 
   OPT 
   PESS 
49  
 
17.31 ± 4.21 
9.94 ± 2.05 
4.63 ± 3.38 
 
8 - 24 
6 - 12 
0 - 12 
NIHSS 49 2.41 ± 2.42 0 - 9 
mRS 47 2.00 (1.00 – 3.00) 0 - 5 
IL-6, pg/ml 35 8.96 ± 8.47 0.53 - 27.35 
TNF-α, pg/ml 35 1.96 ± 2.06 0.02 - 7.52 
CRP, ng/ml 35 2162.34 ± 1665.16 78.43 - 5674.61 
Note. S.D., Standard deviation; IQR, Interquartile range; OPT, Optimism subscale; PESS, 
Pessimism subscale, LOT-R, revised Life Orientation Test; NIHSS, National Institutes of 
Health Stroke Scale; mRS, modified Rankin Scale; IL-6, Interleukin 6; TNF-α, Tumor 









Correlation among variables in patients with ischemic stroke at baseline (n=49) 
  OPT PESS LOT-R NIHSS mRS IL-6 TNF-α CRP 
OPT 1.000        
PESS -0.135 1.000       
LOT-R 0.571** -0.878** 1.000      
NIHSS -0.312* 0.334* -0.411** 1.000     
mRS -0.035 0.319* -0.294* 0.158 1.000    
IL-6 -0.010 0.500** -0.439** 0.227 0.424* 1.000   
TNF-α 0.132 -0.218 0.205 -0.128 0.304 0.195 1.000  
CRP -0.476** 0.160 -0.391* 0.099 0.097 0.152 0.251 1.000 
Note. OPT, Optimism subscale; PESS, Pessimism subscale, LOT-R, revised Life Orientation Test; NIHSS, National Institutes of 
Health Stroke Scale; mRS, modified Rankin Scale; IL-6, Interleukin 6; TNF-α, Tumor necrosis factor alpha; CRP, C-Reactive Protein. 




Table 4  
Multiple linear regression analysis for patients’ level of optimism and other clinical 
outcomes at baseline 
Dependent variable Independent variable Estimate Std. Error p value 
NIHSS (n=49) LOT-R -0.270 0.070 0.001** 
 Age -0.030 0.020 0.240 
mRS (n=47) LOT-R -0.110 0.050 0.030* 
IL-6 (n=35) LOT-R -0.750 0.390 0.067 
 Age 0.310 0.100 0.004 
 NIHSS 0.480 0.650 0.471 
 mRS 0.570 0.900 0.533 
  NSSQ -0.450 0.410 0.286 
TNF-α (n=35) LOT-R 0.030 0.080 0.750 
  Age 0.050 0.030 0.090 
CRP (n=35) LOT-R -148.570 61.770 0.020* 
Note. LOT-R, revised Life Orientation Test; NIHSS, National Institutes of Health Stroke 
Scale; mRS, modified Rankin Scale; IL-6, Interleukin 6; TNF-α, Tumor necrosis factor 
alpha; CRP, C-Reactive Protein; NSSQ, Need of Support and Service Questionnaire; 










The levels of variables at baseline and three-month follow-up (n=13) 
Variables 
Baseline 3-month 
p value Mean ± S.D. 
Median (IQR) 
Range 




   LOT-R 
   OPT 
   PESS 
 
15.62 ± 4.41 
6.62 ± 2.44 
6.00 ± 3.72 
 
8 - 22 
6 - 12 
1 - 12 
 
14.69 ± 5.30 
9.38 ± 2.53 
6.69 ± 3.71 
 
4 - 20 
4 - 12 





NIHSS 3.08 ± 2.93 0 - 9 0.92 ± 2.06 0 - 6 0.004* 
mRS 3.00 (1.5 - 4.5) 0 - 5 2.00 (0.5 - 3.5) 0 - 4 0.003* 
IL-6, pg/ml 11.81 ± 8.75 0.76 - 25.48 2.76 ± 1.65 0.94 - 5.72 0.006* 
TNF-α, pg/ml 2.09 ± 1.77 0.10 - 6.29 1.68 ± 2.13 0.19 - 8.01 0.507 
CRP, ng/ml 2530.28 ± 1857.52 78.43 - 5674.61 19.41 ± 20.67 1.38 - 59.24 0.001* 
Note. S.D., Standard deviation; IQR, Interquartile range; OPT, Optimism subscale; PESS, Pessimism subscale, LOT-R, revised Life 
Orientation Test; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; IL-6, Interleukin 6; TNF-α, Tumor 







Linear mixed model analysis for patient’s level of optimism and other clinical outcomes 
over a three-month post-stroke period (n=13) 









NIHSS Time T2 vs T1 -2.25** 0.48  -3.27 to -1.24 
 LOT-R -0.23** 0.06  -0.36 to -0.11 
 Age -0.02 0.02  -0.06 to 0.02 
mRS Time T2 vs T1 -0.79* 0.28  -1.38 to -1.96 
 LOT-R -0.07 0.04  -0.16 to 0.01 
  NIHSS 0.06 0.08  -0.1 to 0.22 
 









IL-6 Time T2 vs T1 -8.08** 2.37  -12.91 to -3.25 
 LOT-R -0.79** 0.27  -1.33 to -0.25 
 Age 0.32** 0.08  0.16 to 0.47 
 NIHSS 0.55 0.48  -0.42 to 1.52 
 mRS 0.12 0.67  -1.26 to 1.49 
TNF-α Time T2 vs T1 -0.24 0.71  -1.69 to 1.22 
 LOT-R 0.01 0.07  -0.12 to 0.15 
CRP Time T2 vs T1 -2558.82** 553.62  -3684.90 to -1432.74 
 LOT-R -116.5* 56.29  -230.95 to -2.05 
  NIHSS -59.08 112.023  -287.07 to 168.91 
Note. LOT-R, revised Life Orientation Test; NIHSS, National Institutes of Health Stroke 
Scale; mRS, modified Rankin Scale; IL-6, Interleukin 6; TNF-α, Tumor necrosis factor 
alpha; CRP, C-Reactive Protein; T1, baseline; T2, 3-month follow-up; Linear mixed 
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